Source:http://linkedlifedata.com/resource/pubmed/id/15124679
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2004-5-4
|
pubmed:abstractText |
Recently, the water-soluble bifunctional alkylating agent treosulfan demonstrated broad stem cell toxicity, immunosuppressive as well as antileukemic activity. Due to its well known low non-hematologic toxicity profile, treosulfan was considered an alternative agent for conditioning prior to allogeneic transplantation. A first clinical study, combining 3 x 10 g/m2 of treosulfan with 5 x 30 mg/m2 of fludarabine, demonstrated the feasibility of this conditioning. A fast, reliable and complete development of the donor hematopoiesis was evident as well as a low non-hematologic toxicity, transplantation-related mortality and relapse rate. In a second study treosulfan was escalated from 3 x 10 to 3 x 12 and 3 x 14 g/m2. In this protocol, 55 pts (patients) not amenable to standard conditioning suffering from various hematological malignancies were included. Complete donor chimerism was reached by day 28 in 80% of the pts. So far, 8 pts (11%) died without disease progression and 11 pts (20%) relapsed. Treosulfan was very well tolerated. Especially no hepatic VOD, severe cardiac or pulmonary toxicity was noted. Acute GvHD (degrees 11-IV) occurred in 44% and chronic GvHD in 45% of pts. Considering the poor prognosis of these study populations, treosulfan-based conditioning is considered to be safe and efficient. New phase 11 clinical protocols in AML and MDS will be initiated.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0939-5555
|
pubmed:author |
pubmed-author:AschanJJ,
pubmed-author:BlajDD,
pubmed-author:CasperJJ,
pubmed-author:DoelkenGG,
pubmed-author:FreundMM,
pubmed-author:GiebelSS,
pubmed-author:HolowieckiJJ,
pubmed-author:KnaufWW,
pubmed-author:KrogerNN,
pubmed-author:RuutuTT,
pubmed-author:Schafer-EckartKK,
pubmed-author:VolinLL,
pubmed-author:WandtHH,
pubmed-author:ZanderAA
|
pubmed:issnType |
Print
|
pubmed:volume |
83 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S70-1
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15124679-Busulfan,
pubmed-meshheading:15124679-Humans,
pubmed-meshheading:15124679-Leukemia,
pubmed-meshheading:15124679-Leukemia, Myeloid, Acute,
pubmed-meshheading:15124679-Leukocyte Transfusion,
pubmed-meshheading:15124679-Lymphoma,
pubmed-meshheading:15124679-Myelodysplastic Syndromes,
pubmed-meshheading:15124679-Stem Cell Transplantation,
pubmed-meshheading:15124679-Transplantation, Homologous,
pubmed-meshheading:15124679-Transplantation Conditioning,
pubmed-meshheading:15124679-Vidarabine
|
pubmed:year |
2004
|
pubmed:articleTitle |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
|
pubmed:affiliation |
University of Rostock, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|